Praxis reports prelim. cash of ~$925M as of Dec 31, 2025

Praxis Precision Medicines, Inc.

Cash, cash equivalents and marketable securities approx. $925M as of Dec 31, 2025.
Data is preliminary, unaudited, and subject to completion of year-end closing procedures.
No other financial results (revenue, EPS) were disclosed; company is a pre-revenue biotech.
Independent auditor has not expressed an opinion on this preliminary estimate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.